3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester | 91361-78-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester
• 英文别名: 3-chloro-4-(dimethylaminocarbonylsulphanyl)-phenylacetic acid methyl ester；(3-chloro-4-dimethylcarbamoylsulfanylphenyl)acetic acid methyl ester；methyl [3-chloro-4-[(dimethylamino)carbonylthio]phenyl]acetate；methyl 3-chloro-4-dimethylcarbamoylthio-phenylacetate；(3-chloro-4-dimethylcarbamoylsulfanyl-phenyl)-acetic acid methyl ester；3-chloro-4-dimethylcarbamoylthiophenylacetic acid methyl ester；methyl 2-[3-chloro-4-(dimethylcarbamoylsulfanyl)phenyl]acetate
• CAS: 91361-78-3
• 化学式: C₁₂H₁₄ClNO₃S
• 分子量: 287.767
• InChiKey: CKBNIQPIZLQDPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  71.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 在 sodium methylate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 methyl 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetate
  参考文献：
  名称：

  Phenylacetic acid derivatives as hPPAR agonists

  摘要：

  Beginning with the weakly active lead structure 1, a new series of WAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00115-x
• 作为产物：
  描述：

  3-氯-4-羟基苯乙酸甲酯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 1,4-二氧六环 、 十四烷 为溶剂， 反应 16.0h， 生成 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
  [FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE PPAR

  摘要：

  这项发明提供了化合物，包括这些化合物的药物组合物，以及使用这些化合物来治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或紊乱的方法，特别是PPARδ的活性。

  公开号：

  WO2005113506A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS<br/>[FR] COMPOSES ET COMPOSITIONS SERVANT DE MODULATEURS PPAR
  申请人：IRM LLC

  公开号：WO2005116000A1

  公开（公告）日：2005-12-08

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

  这项发明提供了化合物，包括这些化合物的药物组合物，以及使用这些化合物来治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或紊乱的方法，特别是PPAR的活性。
• Arylthiazolidinedione and aryloxazolidinedione derivatives
  申请人：Merck & Co., Inc.

  公开号：US06399640B1

  公开（公告）日：2002-06-04

  Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr;, &dgr; and/or &ggr; mediated diseases, disorders and conditions.

  5-芳基-2,4-噻唑烷二酮或5-芳基-2,4-噁唑烷二酮，在杂环环的5-位置还带有第二取代基，是PPAR的有效激动剂，因此在糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉粥样硬化、肥胖、血管再狭窄和其他PPAR α、δ和/或γ介导的疾病、紊乱和病况的治疗、控制或预防中是有用的。
• Arylthiazolidinedione derivatives
  申请人：Merck & Co., Inc.

  公开号：US06008237A1

  公开（公告）日：1999-12-28

  Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR .alpha., .delta. and/or .gamma. mediated diseases, disorders and conditions.

  取代的5-芳基-2,4-噻唑烷二酮是PPAR的有效激动剂，因此在糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉粥样硬化、肥胖、血管再狭窄和其他PPAR .alpha.、.delta.和/或.gamma.介导的疾病、紊乱和症状的治疗、控制或预防中有用。
• Synthesis of tritium labelled L783483 - a PPAR<i>δ</i>ligand
  作者：Gunnar Grue-Sørensen、Nicolaj Høj

  DOI：10.1002/jlcr.687

  日期：2003.4

  The potent peroxisome proliferator-activated receptor (PPAR) δ ligand L783483 (3-chloro-4-(3-(7-propyl-3-trifluoromethyl-benzisoxazol-6-oxy)propylsulfanyl)phenylacetic acid) has been labelled with tritium via selective tritium/bromine exchange of 5-bromo-6-(3-bromopropyloxy)-7-propyl-3-trifluoromethyl-benzisoxazole. [3H]-L783483 had a specific activity of 529 GBq/mmol (14.3 Ci/mmol) and a radiochemical purity of 98%. Copyright © 2003 John Wiley & Sons, Ltd.

  强效过氧化物酶体增殖物激活受体（PPAR）δ配体L783483（3-氯-4-(3-(7-丙基-3-三氟甲基-苯并异恶唑-6-氧基)丙基硫基)苯乙酸）通过选择性氚/溴交换5-溴-6-(3-溴丙氧基)-7-丙基-3-三氟甲基-苯并异恶唑与氚标记。[3H]-L783483的比活度为529 GBq/mmol（14.3 Ci/mmol），放射化学纯度为98%。版权 © 2003 John Wiley & Sons, Ltd.
• [EN] ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES<br/>[FR] DERIVES D'ARYLTHIAZOLIDINEDIONE ET D'ARYLOXAZOLIDINEDIONE
  申请人：MERCK & CO INC

  公开号：WO2000078312A1

  公开（公告）日：2000-12-28

  Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or η mediated diseases, disorders and conditions.

  5-芳基-2,4-噻唑烷二酮或5-芳基-2,4-噁唑烷二酮，在杂环环上的5位还带有第二个取代基，是PPAR的有效激动剂，因此可用于治疗、控制或预防糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉粥样硬化、肥胖症、血管再狭窄和其他PPARα、δ和/或η介导的疾病、疾患和病况。